Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  













LY-2109761







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

LY-2109761
Identifiers

  • 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine

CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H27N5O2
Molar mass441.535 g·mol−1
3D model (JSmol)

  • C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6

  • InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2

  • Key:IHLVSLOZUHKNMQ-UHFFFAOYSA-N

LY-2109761 is a synthetic compound which acts as a potent and selective inhibitor for the growth factor receptor TGF beta receptor 1. It is used for research into conditions such as pulmonary fibrosis and cancer.[1][2]

See also[edit]

References[edit]

  1. ^ Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. (April 2008). "LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis". Molecular Cancer Therapeutics. 7 (4): 829–840. doi:10.1158/1535-7163.MCT-07-0337. PMC 3088432. PMID 18413796.
  • ^ Tan QY, Cheng ZS (2018). "TGFβ1-Smad Signaling Pathway Participates in Interleukin-33 Induced Epithelial-to-Mesenchymal Transition of A549 Cells". Cellular Physiology and Biochemistry. 50 (2): 757–767. doi:10.1159/000494241. PMID 30308508. S2CID 52966340.
    • Stub icon

    This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=LY-2109761&oldid=1136088650"
    Categories: 
    ●Kinase inhibitors
     ●Pharmacology stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Articles without EBI source
     ●Chemical pages without ChemSpiderID
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
     ●Articles needing additional categories from August 2022
     ●All stub articles
      


    ●This page was last edited on 28 January 2023, at 18:01 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki